BluePrint Orphan, Inc. is in the process of raising a $120 MM fund for the purpose of Orphan asset co-investment. More information will be provided about this opportunity shortly.
- Rare disease asset addressing <200K US prevalence
- High unmet need
- Minimal marketed competition, with only moderate pipeline competition
- Preclinical through Phase II